^
    Back
    Association details:
    Biomarker:CD38 expression
    Cancer:Multiple Myeloma
    Drug:Darzalex (daratumumab) (CD38 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    ASH 2019
    Title:

    Efficacy of Upfront Daratumumab Combination Regimen in Patients with Newly Diagnosed Multiple Myeloma

    Published date:
    11/06/2019
    Excerpt:
    Studies have combined daratumumab, a human IgGκ monoclonal antibody that targets CD38 which is highly expressed on myeloma cells, with proteasome inhibitors and immunomodulatory agents-based regimens in the first-line treatment of NDMM….Upfront combination regimen with daratumumab significantly improved PFS, ORR, sCR and CR along with negative MRD, compared to control arm in patients with NDMM.
    Secondary therapy:
    bortezomib + melphalan
    DOI:
    https://doi.org/10.1182/blood-2019-123131
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Daratumumab-containing Induction Effects on Stem Cells Mobilization, colLection and Engraftment in Newly Diagnosed Multiple MyelomA Patients.

    Excerpt:
    ...Rate (%) of CD38 expression and clonogenic potential of collected CD34+ cells in both groups.`...
    Trial ID:
    DILEMMA
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    EHA 2018
    Title:

    PRE-TREATMENT CD38 EXPRESSION LEVELS IN MYELOMA CELLS AND CD38-POSITIVE REGULATORY T CELLS AFFECT THE RESPONSE OF RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TO TREATMENT WITH DARATUMUMAB

    Published date:
    05/17/2018
    Excerpt:
    We included 28 relapsed/refractory myeloma patients, who were treated with DARA....We confirmed that pre-treatment levels of CD38 MFI were significantly higher in responders than in non-responders (p = 0.001).